INTRODUCTION
Modified mRNAs have recently gained enormous potential for therapeutic applications in the fields of vaccination 1, 2 and disease treatments. [3] [4] [5] [6] The use of synthetic mRNAs in therapy, aiming to induce production of a specific protein of interest, instead of gene therapy, was described more than two decades ago by Wolff et al. 7 Under normal physiological conditions, this novel therapeutic strategy enables the cellular machinery to produce a specific protein, after the delivery of mRNA to the cytosol. Hence, the genome is not altered, which is a decisive advantage as compared to gene therapy. 8 More recently, specific chemically modified mRNAs that encode for the specific proteins can be generated in large yields, and modifications can be performed to reduce immunogenicity, as well as to increase stability. 9, 10 The use of therapeutic mRNA allows the treatment of diseases associated with missing or defective membrane or cytoplasmic proteins, 11 which is not covered by current substitution therapies. Therefore, mRNA therapy will provide a new and highly promising therapeutic approach in the treatment of monogenetic diseases, such as familial hypercholesterolemia (FH) or alpha-1-antitrypsin deficiency (AATD). Many single-gene disorders are associated with early-onset but chronic diseases, which may lead to severe conditions and therefore necessitate expensive lifelong care. Until now, therapeutic treatment options have been limited for such single-gene disorders. 12 Hence, mRNA therapy could be a highly beneficial alternative. It results in functional protein production by hepatocytes after intravenous (i.v.) injection of the complexed protein-encoding mRNA. 13 In order to be effective, the requirement of such an mRNA-based drug should comprise higher safety, therapeutic efficiency, long availability, improved complexity of drug administration, and lower costs.
In order for the clinical translation of mRNA applications to occur, the engineering of a safe and effective delivery vehicle is required to guarantee protection against nucleases, cellular uptake, and prolonged availability of the mRNA for efficient translation, as well as compatibility with human blood. Another elegant approach would be a vehicle that is able to provide long-lasting and efficient translation of mRNA, as well as being fully compatible with human blood.
In current DNA or small interfering RNA (siRNA) applications, cellular transfection has been achieved with both viral and non-viral vectors. However, viral vectors have limitations, including carcinogenic and immunogenic properties, 14, 15 difficult production, 16 and limited packaging capacity. 17, 18 For non-viral approaches, DNA or RNA is frequently encapsulated with positively charged liposomes and polysomes to form lipoplexes or polyplexes, respectively. 19 The cellular uptake is mainly mediated by either lipoplex endocytosis or endocytosis-like mechanisms. 20, 21 Furthermore, liposome delivery systems have substantial advantages like low batch variability, easy synthesis, scalability, and biocompatibility. 22 It has also been noted that drug delivery systems in the nano-range enhance the pharmacokinetic availability of the encapsulated drugs. 22 Additionally, different drugs encapsulated within liposomes, like siRNA for liver cancer (Alnylam) or amphotericin B for fungal infection (Gilead), were tested by the Food and Drug Administration (FDA) in clinical trials. 23 Many groups, including ours, understand that the translation of mRNA-based therapeutic agents is also dependent on an efficient delivery system, as well as a safe cellular uptake. 17 Therefore, we developed a delivery system for the transfection of therapeutic mRNA using 3b-[N-(N',N'-dimethylaminoethane) carbamoyl](DCCholesterol)/dioleoylphosphatidylethanolamine (DOPE) liposomes. We also give a comprehensive analysis of the advantages of our mRNA-lipoplexes, looking at their transfection efficiency, immunogenicity, duration of protein expression, hemocompatibility, and storage stability. Our data show that the lipoplexes exhibit high transfection efficiencies and no adverse effects in vitro, demonstrating their safety for further in vivo investigations.
RESULTS

Characterization and Transfection Evaluation of Liposomes
The liposomes were generated with the dryfilm method and were extruded through a membrane with a pore size of 200 nm. This procedure creates a homogeneous unilamellar liposome solution ( Figure 1A ). The size and morphology of the liposomes were analyzed with transmission electron microscopy (TEM). The liposomes are round-shaped and are 181.8 ± 39.95 nm in size ( Figure 1B) . Additionally, the encapsulation efficacy of the liposomes was measured and compared with Lipofectamine 2000. Therefore, the samples were incubated with RNA-binding fluorescence dye, and the amount of free mRNA was calculated using a standard curve. It was shown that the liposomes have an equivalent capability to encapsulate mRNA like commercially available Lipofectamine 2000. After complexation of mRNA with liposomes, only 16.19% ± 3.58% of free mRNA was detected. This is comparable to the complexation of mRNA with Lipofectamine 2000, where 17.88% ± 1.07% of free mRNA was detected ( Figure 1C ).
For successful cell transfection, the uptake of liposomes loaded with mRNA via endocytosis is a key factor and was analyzed after the generation of lipoplexes composed of liposomes and EGFP-or AAT-encoding mRNA. After the lipoplexes are incorporated into the cytosol and the lipid layer of the lipoplexes is degraded, the mRNA is released into the cytosol. Then, the translation of mRNA into protein by ribosomes begins. Afterward, the EGFP protein stays inside the cell, and the AAT protein is secreted into the extracellular space ( Figure 2A) . To prove the ability of liposomes to transfect cells with mRNA, cyanine 3 (Cy3)-labeled EGFP-encoding mRNA was used. Therefore, the labeled mRNA was encapsulated in liposomes, and the cells were transfected with lipoplexes for 24 hr. After that, fluorescence microscopy was performed to detect the Cy3-labeled mRNA and the translated EGFP protein inside the cells. Both Cy3-labeled mRNA and the EGFP protein were detected inside the cells 24 hr after transfection with lipoplexes ( Figure 2B ).
To determine the optimal ratio of liposomes to mRNA for best cellular transfection, we complexed different amounts of liposomes (1-5 mL) with 1 mg of EGFP mRNA and added them to the cells in full medium for 48 or 120 hr. The percentage of EGFP-expressing cells was significantly increased to 37.8% ± 7.2% at 48 hr after EGFP mRNA transfection with 1 mL of liposomes. However, the use of 2.5 or 5 mL of liposomes resulted in an even higher number of transfected cells, i.e., 47.7% ± 14.8% and 57.9% ± 3.7%, respectively ( Figure 3A ). The fluorescence intensity was similar in all tested liposome concentrations ( Figure 3B ). After 120 hr of transfection, the number of EGFP-expressing cells increased significantly to 32.6% ± 4.7% with 1 mL of liposomes to 77.1% ± 8.26% with 2.5 mL of liposomes and to 59.21% ± 2.98% using 5 mL of liposomes ( Figure 3C ). The highest fluorescence intensity was detected in cells transfected with 2.5 mL of liposomes ( Figure 3D ). Because the best transfection efficiencies were achieved when 2.5 mL of liposomes was used for the encapsulation of 1 mg of mRNA, this liposome volume was used for all further transfection experiments.
Effect of Liposomes on Immunogenic Reactions and Cell Viability after Long-Time Transfection
The viability and immunogenic reactions of cells were analyzed with the help of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and real-time qPCR, respectively. To detect effects of liposomes on cell viability, the cells were transfected with 2.5 and 5 mL of empty liposomes, as well as with 2.5 and 5 mL of liposomes containing 1 mg of EGFP mRNA in full media for 72 and 120 hr. Our data show that neither liposomes nor liposomes containing mRNA significantly influence cell viability ( Figure 4A ).
For the detection of possible immune reactions, cells were treated with empty liposomes or liposomes containing 1 mg of EGFP mRNA. After 24, 72, and 120 hr, the RNA of the cells was isolated and reverse transcribed into copy DNA. After that, the expression of early inflammatory markers, i.e., interferon-a (IFN-a), interferon-b (IFN-b), tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a housekeeping gene, was analyzed using real-time qPCR. Only a very weak, insignificant increase in IFN-a and IFN-b was detected 72 hr after transfection of 
Usability of Liposomes for Therapeutic mRNA Applications
In order to analyze the ability of the liposomes for therapeutic applications, we used an AAT-encoding mRNA, which could also be employed for the effective treatment of AATD. 3 In order to analyze the time of AAT production, which is a prerequisite for subsequent drug development, we transfected cells with either 2.5 mL of empty liposomes or 2. Interestingly, an increase in AAT protein concentration of even more than 3.5 times (from 100.75 ± 2.37 ng/mL to 345.96 ± 8.52 ng/mL) was detected 72 hr after transfection. However, in the supernatants of cells transfected with AAT-encoding mRNA encapsulated with Lipofectamine 2000, no AAT protein was measured 72 hr posttransfection.
Optimal Storage Conditions for mRNA Encapsulated in Liposomes
With regard to the storage requirements for a ready-to-use mRNAbased therapeutic agent, different storage conditions were tested. There- fore, EGFP mRNA was encapsulated into liposomes and stored at different temperature conditions (room temperature [RT], 4 C, À20 C, and À80 C) for 80 days. After storage, fresh lipoplexes as well as stored lipoplexes were added to the cells and incubated for 48 hr. Next, the amount of EGFP-expressing cells was measured. Our data show that the optimal storage temperature for lipoplexes is 4 C. The expression of EGFP is significantly higher (****p < 0.0001) compared to the control group, and the amount of EGFP-positive cells was not significantly different compared to cells transfected with freshly generated lipoplexes ( Figure 6 ).
Hemocompatibility of the Liposomes and Liposomes Containing mRNA with Human Whole Blood
The hemocompatibility of the lipoplexes plays a pivotal role for potential clinical translation and its systemic i.v. application in patients; therefore, we analyzed various hematological markers in our study. 24 After incubation of liposomes or lipoplexes with fresh human whole blood, various hematological markers indicating the activation of the coagulation and complement cascades, as well as activation of platelets and granulocytes, were measured in blood plasma samples using specific ELISAs. It was shown that neither the liposomes nor the lipoplexes have a negative impact on blood. The levels of thrombinantithrombin (TAT) III formation ( Figure 7A ), as well as of the terminal complement complex SC5b-9 ( Figure 7B ), were not significantly different compared to the control and the liposome groups. Moreover, no difference in polymorphonuclear (PMN)-elastase ( Figure 7C ) and the platelet activation marker b-thromboglobulin ( Figure 7D ) was detectable between the groups after incubation. Additionally, blood cell counts, i.e., red blood cells (RBC), white blood cells (WBC), and platelets, were measured before and after incubation in all samples ( Figures 8A-8C) . Again, no differences were found. Likewise, no changes in hemoglobin (HGB) und hematocrit (HCT) values were measured ( Figures 8D and 8E ).
DISCUSSION
Our data illustrate the potential of DC-cholesterol/DOPE liposomes for mRNA transfection, showcasing their high encapsulation efficacy, complete hemocompatibility, as well as the absence of toxic and immunogenic effects. The DC-cholesterol/DOPE liposomes ensure the availability of mRNA inside the cells and keep the expression of the investigated therapeutic protein high over time. In addition, mRNA encapsulated into liposomes can be stored at 4 C for at least 80 days, without loss of function and transfection efficacy.
In line with previous studies, DC-cholesterol exhibits excellent biocompatibility and stability, 25 whereas the neutral lipid DOPE was reported to increase transfection efficiencies. 26 Farhood et al. 26 and Ciani et al. 27 reported that DC-cholesterol and DOPE are the most potent lipids for the formulation of liposomes. In addition, Zhang et al. 28 showed that a 1:2 ratio of DC-cholesterol/DOPE in the formulation results in optimal cellular transfection efficiencies using other nucleic acids, like plasmid DNA and siRNA. Our TEM analysis indicates that the liposomes that have been generated are round and have a diameter of around 200 nm. In agreement with the study by Yang et al., 29 these liposomes were generated by the dry-film method; therefore, we also observed stable, homogeneous distribution in solution, and there was no formation of aggregates.
One of the most important properties for the therapeutic mRNA approach is the encapsulation efficacy of its vehicle system. In the case of DC-cholesterol/DOPE liposomes, which are positively charged, the formation of lipoplexes with the negatively charged mRNA occurs spontaneously. 29 Our results demonstrated similar mRNA encapsulation efficacy of the generated DC-cholesterol/DOPE as compared to the commercially available transfection agent, Lipofectamine 2000.
A number of parameters, including liposomes/mRNA lipoplexes, cell surface fusion, internalization, exposition of mRNA from endosomes into the cytosol, and translation efficiency, are critical for successful protein expression. 30 High positively charged amounts of liposomes are recognized by the cells and promote apoptosis and inflammation in cells through the activation of different pathways, like Toll-like receptors (TLRs) or caspase activation. This in turn can lead to the reduced translation of transfected mRNA inside the cells as observed in our study.
We recognized the ratio of liposomes/mRNA plays an important role for efficient transfection; therefore, to address the optimal liposomes/mRNA ratio for cellular transfection, we systematically tested different amounts and optimized our lipoplexes for maximum transfection efficiency.
The positive charge of liposomes also results in electrostatic interactions with the cell membrane leading to fusion or uptake by endocytosis. [31] [32] [33] However, upon the recognition of a high density of positive charges, these interactions may lead to membrane destabilization, pro-apoptotic reactions, and pro-inflammatory reactions, which in turn lead to the activation of nuclear factor kB (NF-kB)-dependent and -independent pathways. 21, 34 In both pathways, the expression of cytokines, such as TNF-a, IL-6, and IFN-b, are triggered. 21, 35, 36 Hence, we analyzed the expression of these cytokines in the cells that were transfected with lipoplexes for 24, 72, or 120 hr. Our results show no expression in TNF-a and IL-6 genes and only weak, not significant, expression of IFN-a and IFN-b. Although some studies have noted that cationic lipids trigger apoptosis in cells via caspase-9 and caspase-8, 37, 38 others have shown that this pro-apoptotic effect can be minimized with the addition of DOPE. 39 There were also indications that the apoptotic effect depends on the ratio of neutral lipids in the liposome formulation, as well as on the size of the created liposomes. 40 We did not observe any viability issues in the cells with our liposomes. This could be because of the low amount of liposomes needed for successful transfection and protein expression in our study.
A safe approach that can provide a long-lasting effect is necessary for the treatment of genetic diseases, such as AATD, because it will minimize the stress and burden of patients. As a proof of concept, we used an AAT-encoding mRNA to demonstrate the possible liposomal therapeutic potential of sustained AAT protein production and measured an increase in AAT supernatant concentration over 3 days. In the human body, the physiological level of AAT is 20-53 mmol/L. 41 For effective lung protection of patients suffering with AATD, 60 mg/kg AAT protein should be supplemented on a www.moleculartherapy.org weekly basis. 42, 43 Previous studies showed that effective therapeutic levels of translated protein might be achieved using a low dosage of mRNA in different models. Pardi et al.'s group 44 showed that i.v. injection of 1.4 mg/kg modified mRNA coding for HIV antibody into HIV-infected mice protected the mice against HIV challenge. It has also been shown that a single intratracheal application of 20 mg of a TLR coding mRNA could lead to better lung functions in asthmatic mice. 45 Moreover, DeRosa and colleagues 11 described a depot-creating effect of cationic lipids containing erythropoietin or factor-IX-encoding mRNA in cells resulting in high protein expression levels of human erythropoietin or factor IX for up to 7 days in vitro and in vivo. As an innovative mRNA-based therapy for AATD treatment, this encapsulated AAT-encoding mRNA could possibly be administered either by systemic i.v. injection, which would result in liver transfection, 13 or through local aerosol application for lung targeting. [46] [47] [48] The optimal dose of AAT lipoplexes as well as the frequency of treatment for therapeutic applications need to be further investigated in appropriate animal models. Furthermore, for efficient transfection of the liver, the size of the liposomes is critical, because the size of endothelial fenestrae in human liver is around 107 nm and hence extravasation can be reduced because of the use of larger liposomes. 49 Therefore, in preparation for future experiments employing AAT mRNA, liposomes with different sizes should be analyzed to ensure efficient transfection of hepatocytes in vivo.
During blood circulation, the lipoplexes encounter major challenges, like macrophage-mediated clearance 50 or aggregation of blood plasma proteins. 51 Studies have shown that liposomes can be easily modified in order to achieve specific organ targeting 22 or extend blood circulation time. 50 Seeing that the hemocompatibility of the liposomes is an important attribute for a therapeutic application, we comprehensively investigated the hemocompatible properties of these mRNA-loaded liposomes using fresh human whole blood according to International Organization for Standardization (ISO) 10993-4. We demonstrated that neither the liposomes nor the lipoplexes altered any of the investigated blood parameters; hence, this mRNA delivery system fulfills the requirements of ISO 10993-4.
In order to advance this approach to future clinical use, factors such as drug stability, shelf life, and storage conditions are important and must be investigated. These results are in accordance with a study by Yang et al., 29 which demonstrated that their liposomes show no aggregation after 2 months. Maitani et al. 52 also reported that their liposomes are stable and retain the ability to transfect cells for at least 6 months. Our data indicate that our lipoplexes can be safely stored at 4 C for at least 80 days and do not undergo a change in transfection efficiency.
In conclusion, the present study shows that DC-cholesterol/DOPE liposomes can be used as highly functional delivery vehicles for mRNA with high encapsulation efficiency. These lipoplexes result in high transfection efficiencies and sustained protein production, creating a depository effect inside the cells. The lipoplexes enable long-term storage without affecting their efficiency. More importantly, they were highly hemocompatible, and no adverse effects on cell viability or cellular immune response were observed. The generated DC-cholesterol/DOPE liposomes fulfill the necessary safety aspects facilitating the therapeutic delivery of mRNA in various therapeutic settings and representing a substantial contribution to the future development of novel mRNA-based therapeutics.
MATERIALS AND METHODS
In Vitro Transcription of Nucleotide-Modified mRNA
The synthesis of modified mRNA via in vitro transcription (IVT) was described earlier. 53, 54 Briefly, the plasmid DNA sequences of EGFP and AAT (Eurofins Medigenomix) were multiplied by using HotStar HiFidelity Polymerase Kit (QIAGEN), as well as a forward primer (5 0 -TTG GAC CCT CGT ACA GAA GCTA ATA CG-3 0 ; Ella Biotech) and a reverse primer (poly T-tail of 120 thymidines [T 120 ] 5 0 -CTT CCT ACT CAG GCT TTA TTC AAA GAC CA-3 0 ; Ella Biotech). After subsequent purification (QIAquick PCR purification kit; QIAGEN) and gel electrophoresis, the DNA was used as a template for IVT using the MEGAscript T7 kit (Ambion). The following mRNA modifications were implemented: 3 0 -0-Me-m 7 G(5 0 )ppp(5 0 )G RNA cap structure analog (ARCA; New England Biolabs), pseudouridine-5 0 -triphosphate (TriLink Biotech), and 5-methylcytidine-5 0 -triphosphate (TriLink Biotech). For the fluorescent labeling of the mRNA, cy3-cytidine-triphosphate (PerkinElmer) was used. For RNase inhibition, an RNase inhibitor (Thermo Scientific) was added. The reaction mix was incubated for 4 hr at 37 C. Afterward, the mRNA was purified with RNeasy kit (QIAGEN), dephosphorylated using the Antarctic Phosphatase kit (New England Biolabs), purified again, and controlled with 1% agarose gel.
Generation of Liposomes
The liposomes were generated with the dry-film method. 55, 56 Therefore, the cationic lipid DC-cholesterol (3b-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride; Avanti Polar Lipids) and the neutral lipid DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; Avanti Lipids), both dissolved in chloroform, were mixed together in the ratio of 1:2 in a glass flask. Drying of the lipids took place under argon gas flow excluding O 2 . To remove chloroform completely, we put the glass flask with the formed lipid cake into an evaporator overnight. After the evaporation, the lipid cake was rehydrated with nuclease-free H 2 O (QIAGEN). After several minutes of vortexing, the glass flask with the formed multilamellar liposomes was placed in a sonication bath for 30 min to form unilamellar liposomes. Finally, the lipids were extruded with the mini extruder using a membrane with 200 nm pores (Avanti Polar Lipids).
Electron Microscopy
Liposomes from suspension are adsorbed onto a carbon-coated grid, washed, incubated with uranyl acetate, and visualized by negative staining using a Zeiss LIBRA 120 transmission electron microscope (Carl Zeiss) operating at 120 kV.
Encapsulation Efficiency of Liposomes
To test the capsulation efficiency of the liposomes, we used the Quant-iT RiboGreen assay (Invitrogen). Therefore, the standard curve and the samples were prepared. For the standard curve, EGFP mRNA was diluted in different concentrations in water ranging from 0 to 1,000 ng. Additionally, lipoplexes were formed by mixing 1 mg of EGFP mRNA and liposomes or Lipofectamine 2000 (Invitrogen) and incubated for 20 min at RT. Afterward, the RiboGreen fluorescent dye was added to the samples and incubated for 5 min. Fluorescence of samples was measured at 530 nm using a Mithras microplate reader (Berthold Technologies), and the concentration of each sample was calculated using a standard curve. incubation of cells with the transfection complexes for 4 hr at 37 C and 5% CO 2 , the transfection medium was replaced by cell full medium. The analysis of the cells was performed 24 or 72 hr later. With regard to the transfection with liposomes, different amounts of liposomes (1-5 mL) were mixed with 1 mg of EGFP or AAT-encoding mRNA and incubated for 20 min at RT. After this incubation, the liposome complexes were added to the full cell culture medium. After different time points (24, 48, 72 , or 120 hr) the cells were analyzed by flow cytometry (FACScan; Becton Dickinson) or the supernatants were collected and centrifuged at 3,000 Â g and 4 C for 10 min.
AAT ELISA
To determine the concentration of human AAT in the supernatants of cells transfected with AAT-encoding mRNA encapsulated in liposomes or Lipofectamine 2000, we implemental a specific ELISA (Abcam) according to the manufacturer's instructions.
Viability Assay
The MTT (AppliChem) assay was used to verify the viability of transfected A549 cells. Therefore, 150,000 cells/well were seeded in a six-well plate and transfected with different concentrations of mRNA/liposome complexes. After 72 and 120 hr, the cells were washed with PBS (without Ca 2+ /Mg 2+ ; GIBCO) and incubated with 250 mg of MTT dissolved in RPMI 1640 (without phenol red; GIBCO) for 4 hr at 37 C. Subsequently, the MTT solution was removed and the cells were incubated for 10 min at 37 C with 500 mL of DMSO (dimethyl sulfoxide; Serva). The absorbance was measured at 540 nm using the Mithras microplate reader (Berthold).
Real-Time qPCR
The immune reaction of the cells that might be potentially triggered after liposomal transfection was investigated using real-time qPCR. Therefore, A549 cells were transfected with liposomes and lipoplexes containing 1 mg of EGFP mRNA as described above. After an incubation time of 24, 72, and 120 hr, total RNA was isolated from the cells with Aurum total RNA isolation kit (Bio-Rad), and the isolated RNA was converted to copy DNA using the iScript kit (Bio-Rad). Expression of IFN-a, IFN-b, TNF-a, and IL-6 was analyzed. GAPDH expression was used as reference. The real-time qPCR was performed using the CFX Connect Real-Time PCR detection system (Bio-Rad). 
Storage
The lipoplexes were formed by mixing 1 mg of EGFP mRNA and 5 mL of liposomes and stored for 80 days at RT, À4
C, À20 C, or À80 C. After storage, A549 cells seeded 1 day before in 12-well plates were transfected with the respective samples. Fresh lipoplexes were generated and served as controls. After 48 hr of incubation, flow cytometric analysis was performed.
Hemocompatibility Assay
Blood samples were collected by venipuncture of five healthy volunteers. The procedures were approved by the Ethics Committee of the University Hospital of Tübingen. Written informed consent was obtained from all subjects before blood sampling, and the collected blood was anticoagulated with 1.5 IU/mL heparin (Rathiopharm). The following exclusion criteria to guarantee good blood quality have been strictly fulfilled: drug intake in the last 14 days before blood sampling, especially hemostasis-affecting agents like acetylsalicylic acid, oral contraceptives, and cigarettes.
To prove the compatibility of human blood with the generated liposomes and lipoplexes, we directly transferred the heparinized blood after blood sampling into EDTA, a mixture of citrate, theophylline, adenosine, and dipyridamole (CTAD), and citrate monovettes (Sarstedt AG) in order to get baseline values of various hemocompatibility markers. Liposomes (fc: 5 mL/mL) and EGFP mRNA encapsulated in liposomes (fc: 5 mL/mL lipoplexes and 1 mg/mL EGFP mRNA) were incubated in 12 mL of fresh human blood in round polypropylene bottom tubes (BD Falcon) at 37 C for 90 min under dynamic conditions. After incubation, blood was collected and transferred into the respective terminating media including EDTA, CTAD, and citrate. The EDTA-anticoagulated blood was used to analyze whole blood counts. Afterward, all blood samples were centrifugated followed by blood plasma collection and storage at À20 C or À70 C until the analysis of various hemocompatibility markers was performed as previously described. 24 
Statistics
Data are presented as means with error of the mean (SEM). The Kolmogorov-Smirnov test was used to test for normal distribution. To analyze differences between the groups, we executed different analysis tests. Data with normal distribution were analyzed using one-way ANOVA with Bonferroni's multiple comparison test, and data with non-normal distribution were analyzed using the Kruskal-Wallis test. All analyses were performed using the statistical software package GraphPad Prism (version 6; GraphPad Software). Statistical significance was defined as p < 0.05. 
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